NovoCure Ltd Net Income Loss

• NovoCure Ltd showed an increase of +19.2% in Net Income Loss from 2024 to 2025.
• This data is from NovoCure Ltd's annual report (Form 10-K), filed with the SEC on February 26, 2026.
• XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 13 years of available data (2013 to 2025), NovoCure Ltd's Net Income Loss has declined by 76.1%.
• Historical annual values: Fiscal year 2025: -$136.23 million | Fiscal year 2024: -$168.63 million | Fiscal year 2023: -$207.04 million | Fiscal year 2022: -$92.53 million | Fiscal year 2021: -$58.35 million | Fiscal year 2020: $19.81 million | Fiscal year 2019: -$7.23 million | Fiscal year 2018: -$63.56 million | Fiscal year 2017: -$61.66 million | Fiscal year 2016: -$131.85 million | Fiscal year 2015: -$111.58 million | Fiscal year 2014: -$80.68 million | Fiscal year 2013: -$77.37 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026